Dare Bioscience director granted 10,000 stock options
Dare Bioscience, Inc. director Gregory W. Matz received a grant of stock options covering 10,000 shares of common stock.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Dare Bioscience, Inc. director Gregory W. Matz received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.03 per share and expire on June 11, 2036. They vest in full on the earlier of the first anniversary of the grant date or immediately before the first annual stockholder meeting after the grant date, subject to his continued board service, and become fully exercisable upon a change in control.
Insider Trade Summary
Grant/Award: 10,000 shares
Grant/Award
1 txn
Insider
Matz Gregory W
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 10,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 10,000 contracts (Direct)
Footnotes (1)
- F1. This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer.
Key Figures
Options granted: 10,000 options
Exercise price: $2.03 per share
Expiration date: June 11, 2036
+2 more
5 metrics
Options granted
10,000 options
Stock Option (right to buy) granted to director
Exercise price
$2.03 per share
Option exercise price for Dare Bioscience common stock
Expiration date
June 11, 2036
Option expiration for director grant
Underlying shares
10,000 shares
Common stock underlying the option grant
Post-grant derivative holdings
10,000 options
Total options held directly after this transaction
Key Terms
Stock Option (right to buy), change in control, annual meeting of stockholders, exercise price
4 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
change in control financial
"will become exercisable in full upon a change in control of the issuer"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
annual meeting of stockholders financial
"immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date"
exercise price financial
"conversion_or_exercise_price: 2.0300"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Dare Bioscience (DARE) director Gregory W. Matz receive in this Form 4?
Gregory W. Matz received a grant of stock options for 10,000 shares of Dare Bioscience common stock. These options are part of his director compensation and give him the right to buy shares at a fixed exercise price if vesting conditions are met.
What is the exercise price of the Dare Bioscience (DARE) stock options granted to Gregory W. Matz?
The options granted to Gregory W. Matz have an exercise price of $2.03 per share. This is the price he can pay to purchase Dare Bioscience common stock once the options vest and are exercisable, subject to the terms of the award.
How many Dare Bioscience (DARE) options does Gregory W. Matz hold after this transaction?
After this transaction, Gregory W. Matz holds 10,000 stock options for Dare Bioscience common stock. This Form 4 shows the newly granted award and the resulting option position reported as directly owned following the grant.
When do Gregory W. Matz’s Dare Bioscience (DARE) stock options vest?
The options vest in full on the earlier of the first anniversary of the grant date or immediately before Dare Bioscience’s first annual stockholder meeting after the grant. Vesting is conditioned on his continued service as a director through that vesting event.
What happens to Gregory W. Matz’s Dare Bioscience (DARE) options if there is a change in control?
If Dare Bioscience undergoes a change in control, the options become fully exercisable. This means all 10,000 options would be immediately exercisable, regardless of the normal vesting schedule, under the terms described in the footnote.
What is the expiration date of Gregory W. Matz’s Dare Bioscience (DARE) stock options?
The stock options granted to Gregory W. Matz expire on June 11, 2036. After that date, any unexercised options will no longer be usable, so exercises must occur before this expiration under the plan’s terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
